Mirada Medical
Enabling a New Teleradiology Paradigm for Oncology Dosimetry

External beam radiation therapy (EBRT) remains the gold standard for more than half of cancer patients. However, molecular radiotherapy, where the radioactive agent is injected into the body, is rapidly emerging as a new, personalized, and precise technology to both diagnose and treat cancer. The success of both EBRT and MRT hinges on the accuracy of the radiation dose administered to a patient.

Mirada Medical, a frontrunner in radiology innovations, excels in the science of dosimetry.

Mirada has licensed a next-gen, cloud-based teleradiology platform to TeleDaaS, which provides dosimetry-as-a-service to hospitals who are treating cancer patients with MRT. TeleDaaS service covers a range of therapeutic radiopharmaceuticals, which started with yttrium (Y90) and is expanding to cover iodine (I131), lutetium (Lu177), and actinium (Ac255), TeleDaaS will provide a complete solution for personalized dosimetry with solutions Mirada developed over the last 8 years.

These applications have been proven in clinical trials to deliver highly accurate and clinically impactful dosimetry plans to accelerate dosimetry planning and improving Y-90, Lu-177 workflows for personalized cancer care.

“Originally developed for a standalone workstation, we transformed our dedicated workstations into a zero-footprint solution to power TeleDaaS as a physician-owned virtual medical practice across the country,” says Jon DeVries, CEO of Mirada Medical.

Our solutions have exhibited phenomenal clinical outcomes for patients with liver cancers by increasing the dose that can be given safely to patients. Personalized dose plans have been shown to double the response to Y90 treatment in liver cancer patients, with patients achieving a nearly 150 percent increase in life expectancy from 10 months to around two and a half years. The tumor can be ablated or shrunk and removed by surgery, significantly improving patient care.

Built on these proven clinical benefits, TeleDaaS addresses the four major challenges around people, process, technology, and economics.

A huge mismatch exists between the market demand for skilled radio-pharmacists and available graduates to support new radiopharmaceuticals rolling out every year. TeleDaaS bridges the gap in staffing with its specialty teleradiology service, providing hospitals with access to experts in a single click.

Its remote service helps physicians save roughly an hour of effort per patient rather than pulling a physician and a physicist out of their routine on-site for an extended period. Health systems can easily integrate TeleDaaS’ dose plans into their existing clinical workflows so that the treating physicians can easily access the results and share them with their patients. TeleDaaS specialists are also available to consult with the local treating physicians.

Billing for MRT dosimetry provides unique workflow challenges. TeleDaaS addresses this by comprehensively documenting clinical necessity, generating the appropriate evidence, and obtaining the required signatures. This package can be provided to the hospital to streamline the billing process and obtain appropriate reimbursement.

Traditionally, the software application is purchased by a customer and then installed in their network. Many customers are reluctant to implement the software as it entails an upfront cost, requires a new server, which can increase their operational costs, and has to be vetted from a security perspective. And because the IT department has many demands on its time, implementation can sometimes take quite a while. But with TeleDaaS’ cloud-based service, Mirada helped them use their existing systems (enterprise PACS) and workflows without needing to install anything on site, write any storage, or acquire a new interface. This reimbursable service resolved the customer’s workflow and economic issues.

Originally developed for a standalone workstation, we transformed our dedicated workstations into a zero-footprint solution to power TeleDaaS as a physician-owned virtual medical practice across the country

At the top of Mirada’s business goals is its commitment to delivering exceptional customer experience. It ensures a seamless onboarding process, from documenting clients’ requirements and solution planning to sales, software implementation, and ongoing support. Its support team regularly performs annual and quarterly customer surveys to obtain two-way feedback as part of its quality management system.

Amassing decades-long unparalleled expertise in diagnostic imaging, external beam radiation therapy (RT), and interventional radiology, Mirada holds a long history of developing advanced medical imaging and AI-powered automation tools. It is a one-stop destination for deep learning and multiple medical imaging technologies like PET, CT, image analysis and registration, longitudinal tracking, and diagnostics, providing simple and accessible solutions to complex image analysis problems.

Its diagnostic imaging software, Mirada XD, offers a complete set of workflows to boost radiologists’ confidence in interpreting clinical data powered by accurate and flexible tools. RTx and DLCExpert are other image assessment and automation offerings curated for effective cancer treatment to support multiple radiotherapy planning workflows.

Mirada has many successful collaborations with eminent healthcare providers, including Canon Medical, Philips Healthcare, GE Healthcare, Agfa-Gevaert, and Change Healthcare, to achieve industry-wide product distribution. It is FDA-cleared and CE-marked in 30 countries and 32 languages, eliminating hurdles in bringing its products into the market.

Building on its breadth of radiotherapy technologies, Mirada continues to set new benchmarks with its dosimetry-as-a-service, reimagining the role of teleradiology in defining effective radiation exposure for cancer care.